Synergy Pharmaceuticals Announces License Agreement with Luoxin Pharmaceutical Group for TRULANCE (plecanatide) in China Read more
How challenges including Brexit, inadequate funding & insufficient patient sample sizes hinder Orphan Drugs and Rare Diseases research Read more
Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101 Read more
Alteogen Gets FDA Approval for Orphan Drug Designation with an Antibody-Drug Conjugate for Gastric Cancer Read more
Glenmark Pharmaceuticals and Harbour BioMed Sign Agreement for Greater China to Develop GBR 1302 Read more